|
1
|
Pohlmann PR, Mayer IA and Mernaugh R:
Resistance to trastuzumab in breast cancer. Clin Cancer Res.
15:7479–7491. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosenzweig SA: Acquired resistance to
drugs targeting receptor tyrosine kinases. Biochem Pharmacol.
83:1041–1048. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim EG and Kim KM: Strategies and
advancement in antibody-drug conjugate optimization for targeted
cancer therapeutics. Biomol Ther (Seoul). 23:493–509. 2015.
View Article : Google Scholar
|
|
5
|
Kreitman RJ: Recombinant immunotoxins
containing truncated bacterial toxins for the treatment of
hematologic malignancies. BioDrugs. 23:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alewine C, Hassan R and Pastan I: Advances
in anticancer immunotoxin therapy. Oncologist. 20:176–185. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martin-Killias P, Stefan N, Rothschild S,
Plückthun A and Zangemeister-Wittke U: A novel fusion toxin derived
from an EpCAM-specific designed ankyrin repeat protein has potent
antitumor activity. Clin Cancer Res. 17:100–110. 2011. View Article : Google Scholar
|
|
8
|
Zielinski R, Lyakhov I, Jacobs A, Chertov
O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R
and Capala J: Affitoxin - a novel recombinant, HER2-specific,
anticancer agent for targeted therapy of HER2-positive tumors. J
Immunother. 32:817–825. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zielinski R, Lyakhov I, Hassan M, Kuban M,
Shafer-Weaver K, Gandjbakhche A and Capala J: HER2-affitoxin: A
potent therapeutic agent for the treatment of HER2-overexpressing
tumors. Clin Cancer Res. 17:5071–5081. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu H, Seijsing J, Frejd FY, Tolmachev V
and Gräslund T: Target-specific cytotoxic effects on
HER2-expressing cells by the tripartite fusion toxin
ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and
a half-life extension domain. Int J Oncol. 47:601–609.
2015.PubMed/NCBI
|
|
11
|
Mazor R, Vassall AN, Eberle JA, Beers R,
Weldon JE, Venzon DJ, Tsang KY, Benhar I and Pastan I:
Identification and elimination of an immunodominant T-cell epitope
in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc
Natl Acad Sci USA. 109:E3597–E3603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Onda M, Beers R, Xiang L, Nagata S, Wang
Q-C and Pastan I: An immunotoxin with greatly reduced
immunogenicity by identification and removal of B cell epitopes.
Proc Natl Acad Sci USA. 105:11311–11316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu W, Onda M, Lee B, Kreitman RJ, Hassan
R, Xiang L and Pastan I: Recombinant immunotoxin engineered for low
immunogenicity and antigenicity by identifying and silencing human
B-cell epitopes. Proc Natl Acad Sci USA. 109:11782–11787. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Onda M, Beers R, Xiang L, Lee B, Weldon
JE, Kreitman RJ and Pastan I: Recombinant immunotoxin against
B-cell malignancies with no immunogenicity in mice by removal of
B-cell epitopes. Proc Natl Acad Sci USA. 108:5742–5747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
King C, Garza EN, Mazor R, Linehan JL,
Pastan I, Pepper M and Baker D: Removing T-cell epitopes with
computational protein design. Proc Natl Acad Sci USA.
111:8577–8582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vuhai-Luuthi MT, Jolivet A, Jallal B,
Salesse R, Bidart JM, Houllier A, Guiochon-Mantel A, Garnier J and
Milgrom E: Monoclonal antibodies against luteinizing hormone
receptor. Immunochemical characterization of the receptor.
Endocrinology. 127:2090–2098. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Reiter Y, Brinkmann U, Jung SH, Lee B,
Kasprzyk PG, King CR and Pastan I: Improved binding and antitumor
activity of a recombinant anti-erbB2 immunotoxin by disulfide
stabilization of the Fv fragment. J Biol Chem. 269:18327–18331.
1994.PubMed/NCBI
|
|
18
|
Bera TK, Viner J, Brinkmann E and Pastan
I: Pharmacokinetics and antitumor activity of a bivalent
disulfide-stabilized Fv immunotoxin with improved antigen binding
to erbB2. Cancer Res. 59:4018–4022. 1999.PubMed/NCBI
|
|
19
|
Schmidt M, McWatters A, White RA, Groner
B, Wels W, Fan Z and Bast RC Jr: Synergistic interaction between an
anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA]
and ionizing radiation for inhibiting growth of ovarian cancer
cells that overexpress HER-2. Gynecol Oncol. 80:145–155. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang L, Liu B, Schmidt M, Lu Y, Wels W and
Fan Z: Antitumor effect of an HER2-specific antibody-toxin fusion
protein on human prostate cancer cells. Prostate. 47:21–28. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shinohara H, Morita S, Kawai M, Miyamoto
A, Sonoda T, Pastan I and Tanigawa N: Expression of HER2 in human
gastric cancer cells directly correlates with antitumor activity of
a recombinant disulfide-stabilized anti-HER2 immunotoxin. J Surg
Res. 102:169–177. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kreitman RJ, Wilson WH, Bergeron K, Raggio
M, Stetler-Stevenson M, FitzGerald DJ and Pastan I: Efficacy of the
anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant
hairy-cell leukemia. N Engl J Med. 345:241–247. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thurber GM, Schmidt MM and Wittrup KD:
Antibody tumor penetration: Transport opposed by systemic and
antigen-mediated clearance. Adv Drug Deliv Rev. 60:1421–1434. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Löfblom J, Feldwisch J, Tolmachev V,
Carlsson J, Ståhl S and Frejd FY: Affibody molecules: Engineered
proteins for therapeutic, diagnostic and biotechnological
applications. FEBS Lett. 584:2670–2680. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Orlova A, Magnusson M, Eriksson TLJ,
Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J,
Tolmachev V, Ståhl S, et al: Tumor imaging using a picomolar
affinity HER2 binding affibody molecule. Cancer Res. 66:4339–4348.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tolmachev V, Rosik D, Wållberg H, Sjöberg
A, Sandström M, Hansson M, Wennborg A and Orlova A: Imaging of EGFR
expression in murine xenografts using site-specifically labelled
anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule:
aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging.
37:613–622. 2010. View Article : Google Scholar
|
|
27
|
Tolmachev V, Malmberg J, Hofström C,
Abrahmsén L, Bergman T, Sjöberg A, Sandström M, Gräslund T and
Orlova A: Imaging of insulinlike growth factor type 1 receptor in
prostate cancer xenografts using the affibody molecule
111In-DOTA-ZIGF1R:4551. J Nucl Med. 53:90–97. 2012.
View Article : Google Scholar
|
|
28
|
Tolmachev V, Varasteh Z, Honarvar H,
Hosseinimehr SJ, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L and
Orlova A: Imaging of platelet-derived growth factor receptor β
expression in glioblastoma xenografts using affibody molecule
111In-DOTA-Z09591. J Nucl Med. 55:294–300. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Orlova A, Malm M, Rosestedt M, Varasteh Z,
Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Ståhl S,
et al: Imaging of HER3-expressing xenografts in mice using a (99m)
Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule. Eur J Nucl Med Mol
Imaging. 41:1450–1459. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kramer-Marek G, Shenoy N, Seidel J,
Griffiths GL, Choyke P and Capala J: 68Ga-DOTA-affibody molecule
for in vivo assessment of HER2/neu expression with PET. Eur J Nucl
Med Mol Imaging. 38:1967–1976. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Orlova A, Wållberg H, Stone-Elander S and
Tolmachev V: On the selection of a tracer for PET imaging of
HER2-expressing tumors: Direct comparison of a 124I-labeled
affibody molecule and trastuzumab in a murine xenograft model. J
Nucl Med. 50:417–425. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Heskamp S, Laverman P, Rosik D, Boschetti
F, van der Graaf WT, Oyen WJ, van Laarhoven HW, Tolmachev V and
Boerman OC: Imaging of human epidermal growth factor receptor type
2 expression with 18F-labeled affibody molecule ZHER2:2395 in a
mouse model for ovarian cancer. J Nucl Med. 53:146–153. 2012.
View Article : Google Scholar
|
|
33
|
Lee SB, Hassan M, Fisher R, Chertov O,
Chernomordik V, Kramer-Marek G, Gandjbakhche A and Capala J:
Affibody molecules for in vivo characterization of HER2-positive
tumors by near-infrared imaging. Clin Cancer Res. 14:3840–3849.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lundberg E, Höidén-Guthenberg I, Larsson
B, Uhlén M and Gräslund T: Site-specifically conjugated anti-HER2
Affibody molecules as one-step reagents for target expression
analyses on cells and xenograft samples. J Immunol Methods.
319:53–63. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tolmachev V, Orlova A, Pehrson R, Galli J,
Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J,
Lundqvist H, et al: Radionuclide therapy of HER2-positive
microxenografts using a 177Lu-labeled HER2-specific Affibody
molecule. Cancer Res. 67:2773–2782. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Orlova A, Jonsson A, Rosik D, Lundqvist H,
Lindborg M, Abrahmsen L, Ekblad C, Frejd FY and Tolmachev V:
Site-specific radiometal labeling and improved biodistribution
using ABY-027, a novel HER2-targeting affibody
molecule-albumin-binding domain fusion protein. J Nucl Med.
54:961–968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Altai M, Wållberg H, Honarvar H, Strand J,
Orlova A, Varasteh Z, Sandström M, Löfblom J, Larsson E, Strand SE,
et al: 188Re-ZHER2:V2, a promising affibody-based targeting agent
against HER2-expressing tumors: preclinical assessment. J Nucl Med.
55:1842–1848. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sörensen J, Sandberg D, Sandström M,
Wennborg A, Feldwisch J, Tolmachev V, Åström G, Lubberink M,
Garske-Román U, Carlsson J, et al: First-in-human molecular imaging
of HER2 expression in breast cancer metastases using the
111In-ABY-025 affibody molecule. J Nucl Med. 55:730–735.
2014. View Article : Google Scholar
|
|
39
|
Sörensen J, Velikyan I, Sandberg D,
Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M,
Lubberink M, Olofsson H, et al: Measuring HER2-receptor expression
in metastatic breast cancer using [(68)Ga]ABY-025 Affibody PET/CT.
Theranostics. 6:262–271. 2016. View Article : Google Scholar
|
|
40
|
Makrides SC, Nygren PA, Andrews B, Ford
PJ, Evans KS, Hayman EG, Adari H, Uhlén M and Toth CA: Extended in
vivo half-life of human soluble complement receptor type 1 fused to
a serum albumin-binding receptor. J Pharmacol Exp Ther.
277:534–542. 1996.PubMed/NCBI
|
|
41
|
Andersen JT, Pehrson R, Tolmachev V, Daba
MB, Abrahmsén L and Ekblad C: Extending half-life by indirect
targeting of the neonatal Fc receptor (FcRn) using a minimal
albumin binding domain. J Biol Chem. 286:5234–5241. 2011.
View Article : Google Scholar :
|
|
42
|
Jonsson A, Dogan J, Herne N, Abrahmsén L
and Nygren P-A: Engineering of a femtomolar affinity binding
protein to human serum albumin. Protein Eng Des Sel. 21:515–527.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tolmachev V, Hofström C, Malmberg J,
Ahlgren S, Hosseinimehr SJ, Sandström M, Abrahmsén L, Orlova A and
Gräslund T: HEHEHE-tagged affibody molecule may be purified by
IMAC, is conveniently labeled with [99(m)Tc(CO)3](+), and shows
improved biodistribution with reduced hepatic radioactivity
accumulation. Bioconjug Chem. 21:2013–2022. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Orlova A, Rosik D, Sandström M, Lundqvist
H, Einarsson L and Tolmachev V: Evaluation of
[(111/114m)In]CHX-A″-DTPA-ZHER2:342, an affibody ligand coniugate
for targeting of HER2-expressing malignant tumors. Q J Nucl Med Mol
Imaging. 51:314–323. 2007.PubMed/NCBI
|
|
45
|
Wållberg H and Orlova A: Slow
internalization of anti-HER2 synthetic affibody monomer
111In-DOTA-ZHER2:342-pep2: implications for development of labeled
tracers. Cancer Biother Radiopharm. 23:435–442. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Varasteh Z and Orlova A: Comparing the
measured affinity of 111In-labeled ligands for cellular
receptors by monitoring gamma, beta, or X-ray radiation with three
different LigandTracer® devices. J Radioanal Nucl Chem.
304:823–828. 2015. View Article : Google Scholar
|
|
47
|
Altai M, Strand J, Rosik D, Selvaraju RK,
Eriksson Karlström A, Orlova A and Tolmachev V: Influence of
nuclides and chelators on imaging using affibody molecules:
Comparative evaluation of recombinant affibody molecules
site-specifically labeled with 68Ga and 111In via
maleimido derivatives of DOTA and NODAGA. Bioconjug Chem.
24:1102–1109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gong H, Kovar J, Little G, Chen H and
Olive DM: In vivo imaging of xenograft tumors using an epidermal
growth factor receptor-specific affibody molecule labeled with a
near-infrared fluorophore. Neoplasia. 12:139–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kobayashi H, Kao CH, Kreitman RJ, Le N,
Kim MK, Brechbiel MW, Paik CH, Pastan I and Carrasquillo JA:
Pharmacokinetics of 111In- and 125I-labeled
antiTac single-chain Fv recombinant immunotoxin. J Nucl Med.
41:755–762. 2000.PubMed/NCBI
|
|
50
|
Tolmachev V, Velikyan I, Sandström M and
Orlova A: A HER2-binding Affibody molecule labelled with 68Ga for
PET imaging: Direct in vivo comparison with the
111In-labelled analogue. Eur J Nucl Med Mol Imaging.
37:1356–1367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Barta P, Malmberg J, Melicharova L,
Strandgård J, Orlova A, Tolmachev V, Laznicek M and Andersson K:
Protein interactions with HER-family receptors can have different
characteristics depending on the hosting cell line. Int J Oncol.
40:1677–1682. 2012.
|
|
52
|
Kobayashi H, Yoo TM, Kim IS, Kim MK, Le N,
Webber KO, Pastan I, Paik CH, Eckelman WC and Carrasquillo JA:
L-lysine effectively blocks renal uptake of 125I- or
99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer
Res. 56:3788–3795. 1996.PubMed/NCBI
|
|
53
|
Altai M, Varasteh Z, Andersson K, Eek A,
Boerman O and Orlova A: In vivo and in vitro studies on renal
uptake of radio-labeled affibody molecules for imaging of HER2
expression in tumors. Cancer Biother Radiopharm. 28:187–195. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ahlgren S, Orlova A, Wållberg H, Hansson
M, Sandström M, Lewsley R, Wennborg A, Abrahmsén L, Tolmachev V and
Feldwisch J: Targeting of HER2-expressing tumors using
111In-ABY-025, a second-generation affibody molecule
with a fundamentally reengineered scaffold. J Nucl Med.
51:1131–1138. 2010. View Article : Google Scholar : PubMed/NCBI
|
